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Abstract
Background: YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice
model. The study was conducted to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic
variables, and antitumor activity in advanced solid malignancies.
Methods: This dose-escalation study was conducted according to the Chinese State Food and Drug
Administration (SFDA) recommendations in patients with advanced solid tumors to determine the MTD for orally
administered apatinib. Doses of continuously administered apatinib were escalated from 250 mg. Treatment
continued after dose-escalation phase until withdrawal of consent, intolerable toxicities, disease progression or
death.
Results: Forty-six patients were enrolled. Hypertension and hand-foot syndrome were the two dose-limiting
toxicities noted at dose level of 1000 mg. MTD was determined to be 850 mg once daily. Pharmacokinetic analysis
showed early absorption with a half-life of 9 hours. The mean half-life was constant over all dose groups. Steady-
state conditions analysis suggested no accumulation during 56 days of once-daily administration. The most
frequently observed drug-related adverse events were hypertension (69.5%, 29 grade 1-2 and 3 grade 3-4),
proteinuria (47.8%, 16 grade 1-2 and 6 grade 3-4), and hand-foot syndrome (45.6%, 15 grade 1-2 and 6 grade 3-4).
Among the thirty-seven evaluable patients, PR was noted in seven patients (18.9%), SD 24 (64.9%), with a disease
control rate of 83.8% at 8 weeks.
Conclusions: The recommended dose of 750 mg once daily was well tolerated. Encouraging antitumor activity
across a broad range of malignancies warrants further evaluation in selected populations.
Trial registration: ClinicalTrials.gov unique identifier: NCT00633490
Background
Vascular endothelial growth factor receptors (VEGFRs)
are tyrosine kinases, functioning as a central regulator of
multiple signaling pathways that control angiogenesis.
The VEGFR-family proteins consist of VEGFR-1/Flt-1,
VEGFR-2/KDR/Flk-1, and VEGFR-3/Flt-4 [1,2]. VEGFR-
2 is thought to be principally responsible for angiogen-
esis in malignancies [3]. Various VEGFR-2 inhibitors,
including receptor-specific antibodies and low molecular
weight chemicals such as sorafenib, vandetanib, cedira-
nib, and sunitinib, have recently been developed [4-6].
In addition to the VEGF-A neutralizing antibody, which
is already a standard treatment for late-stage colorectal
cancer in the USA [7], sorafenib was recently approved
by the US Food and Drug Administration for the treat-
ment of renal and hepatic cancers, and sunitinib was
approved for the treatment of gastrointestinal stromal
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of the VEGFR tyrosine kinase inhibitors (TKIs) to gas-
trointestinal adenocarcinoma remains a challenge,
although they have been found to be active for lung,
breast, renal, and hepatic cancers, and GIST.
YN968D1 (apatinib) is an orally administered small-
molecule receptor TKI with potential antiangiogenic and
antineoplastic activities, developed by Advenchen
Laboratories, LLC (Northridge, CA, USA). It is a com-
pound derived from PTK787/ZK222584 (Valatinib) and
has been shown to demonstrate superior in vivo efficacy
compared to valatinib in xenograft study [8]. Apatinib
selectively binds to and inhibits VEGFR-2, which may
inhibit VEGF-stimulated endothelial cell migration and
proliferation and decrease tumor microvascular density
(MVD).
On the basis of encouraging preclinical data, we
initiated this first-in-human clinical study in patients
with advanced solid tumors. The primary objectives
were to determine the maximum-tolerated dose (MTD),
dose-limiting toxicities (DLT), pharmacokinetic (PK)
profiles, and recommended Phase II dose of apatinib. A
secondary objective was to document any antitumor
activity.
Methods
Patient Selection
Patients with histologically or cytologically confirmed
advanced solid malignancies for which no standard
alternative curative therapy was available were eligible.
Other eligibility criteria were age between 18 to 70
years, ability to take medications orally, with or without
measurable lesions, no history of other cancers, an East-
ern Cooperative Oncology Group (ECOG) performance
status between 0 and 2, life expectancy of >3 months.
Additionally, patients had to exhibit adequate hemato-
poietic function (absolute neutrophils count ≥ 1.5 × 10
9/
L, hemoglobin, ≥90 g/L, platelets, ≥100 × 10
9/L), hepatic
function (bilirubin ≤1.5 × upper limit of normal (ULN),
alanine aminotransferase ≤ 2.5 ×ULN, aspartate amino-
transferase <2.5 × ULN), renal function(serum creatinine
≤ 1.5 ×ULN, creatinine clearance rate ≥ 50 ml/min), and
coagulation function (normal prothrombin time, acti-
vated partial thromboplastin time, thrombin time, and
fibrinogen). Patients were excluded if they were preg-
nant or nursing, had a known history of brain metasta-
sis, hypertension, coronary disease or other significant
cardiovascular disease, gastrointestinal disorder or other
factors that could interfere with drug absorption, were
on anti-coagulation therapy, had prior therapy with
anti-VEGF or anti-VEGFR targeting agents. Patients
with a history of any other malignancy, apart from in
situ carcinoma of the cervix or basal cell carcinoma of
the skin were also excluded. Patients could not have
undergone surgery within the last 4 weeks and should
not have been treated within the preceding 4 weeks to
enrollment with any investigational drug, chemotherapy,
radiotherapy, immunotherapy (6 weeks for nitrosureas
and mitomycin C). Written informed consent was
obtained from all patients. The Fudan University Shang-
hai Cancer Center Ethic Committee for Clinical Investi-
gation approved the study.
Study Design
The phase I study was designed in accordance with the
Chinese State Food and Drug Administration (SFDA)
recommendations (Guidance for Industry, 2005). PK
evaluations were to be performed for single-dosing and
multiple-dosing of which the dose levels were deter-
mined after completion of dose-escalation. Three dose
levels (low, intermediate and high dose) for single-dos-
ing and one dose level (the recommended dose for
phase II) for multiple-dosing study, between 8 to 12 par-
ticipants for each dose levels, were required to meet the
SFDA guidance. A cross-over design to evaluate the
effects of food intake was incorporated into the single-
dosing assessment, also meeting the SFDA requirement,
but data will be presented separately.
Apatinib was provided by Advenchen Laboratories,
LLC (Northridge, CA, USA) as capsule to be adminis-
tered orally daily. A safe starting dose was determined
in accordance with SFDA recommendations (Guidance
f o rI n d u s t r y2 0 0 5 )f o l l o w i n gap r e v i o u s l ye s t a b l i s h e d
maximum-tolerated dose (MTD) in dogs for YN968D1
of above 30 mg/kg. Thus, in compliance with the
SFDA’s recommendation, the starting dose was deter-
mined to be 250 mg/day, corresponding to one-fourth
of the MTD in dogs. (ClinicalTrials.gov number:
NCT00633490).
Treatment
Dose-escalation cohorts enrolled three to six patients.
Intrapatient dose escalation was not allowed. DLT was
defined as grade 4 hematologic adverse event (AE), or
grade ≥3 non-hematologic AE (except for nausea and
vomiting that could be improved with optimal suppor-
tive care, escalation of alkaline phosphatase) in the
first 4-week period. If none of the initial 3 patients
developed DLT, dose escalation continued. If one of
the initial 3 patients developed DLT, three additional
patients were enrolled at the same dose level. If none
of the 3 additional patients treated at the same dose
level developed DLT, dose escalation continued. If 2 or
3 of the initial 3 patients treated at a dose level, or 1,
2 ,o r3o ft h ea d d i t i o n a l3p a t i e n t sa tad o s el e v e l
developed DLT, dose escalation ceased. The MTD was
defined as the dose having at most two out of six
patients experience DLT.
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Page 2 of 8Treatment continued after dose escalation phase until
withdrawal of consent, intolerable toxicities, disease pro-
gression or death. During the extended treatment period
(after the first cycle) dose reduction was allowed if
patient experience toxicities.
PK cohorts enrolled 12 to 18 patients for the 3
planned dose level as determined after dose escalation,
and the intermediate-dose cohort would continue to
enter the multiple-dosing evaluation after wash-out
period.
Evaluation of Safety and Tolerability
Medical records and laboratory tests were obtained dur-
ing screening. Physical examination, routine laboratory
evaluations, and performance status were assessed at
baseline and at specified time points throughout the
trial. AEs and concomitant medications were recorded
at the end of each cycle. The safety evaluation period
extended through 30 days from the last dose of study
drug or through recovery to grade 1 or better from all
acute toxicities associated with drug administration.
Toxicity was evaluated and graded according to the
NCI-CTC for Adverse Events, version 3.0.
Evaluation of Antitumor Activity
Patients with measurable disease at baseline were evalu-
ated for tumor response according to the Response Eva-
luation Criteria for Solid Tumors (RECIST) [9].
Radiographic studies (CT scan or MRI) for disease
assessment were conducted at baseline and every 2
cycles (8 weeks) thereafter. The best overall response
was reported. Disease control rate was defined as the
percentage of patients with complete response (CR),
partial response (PR), and stable disease (SD) for at least
8 weeks. The duration of overall response was defined
as the period from the initial measurement of complete
response (CR) or partial response (PR), whichever
occurred first, to the first date of documented disease
recurrence or progression. The same method and tech-
niques of assessment were used to characterize each
identified and reported lesion at baseline and at subse-
quent evaluations.
Pharmacokinetic Analyses
Whole blood samples (1 ml) were collected at 0 (pre-
dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 32, and 48 hours for
single-dosing evaluation and 0, 0.5, 1, 2, 3, 4, 6, 8, 12,
and 24 hours (before the next dose) on days 1, 6, 28,
and 56 for multiple-dosing evaluation. After the last
dose on day 56, two additional samples were collected
at 32 and 48 hours for multiple-dosing assessment.
Plasma was collected from the blood samples following
centrifugation, and stored at -80°C until analysis.
Apatinib concentrations in plasma were determined
using fully validated specific liquid chromatograph/tan-
dem mass spectrometer methods, with a lower limit of
quantitation of 1.6 ng/ml. Based on quality-control sam-
ples that were assayed along with the samples, the intra-
day and interday precision for apatinib analytes ranged
from 4.6% to 9.0%, and the accuracy ranged from 85.6%
to 110%. The PK parameters, including area under the
plasma concentration-time curve (AUC), maximum
plasma concentration (Cmax), time to maximum concen-
tration (tmax), and elimination half-life (t1/2) were deter-
mined by non-compartmental analysis using InnaPhase
Kinetica 2000™ (InnaPhase Corp., Philadelphia, PA,
USA). The linear-logarithmic trapezoidal method was
used to calculate the AUC, and t1/2 lz was calculated by
linear regression of the terminal slope of the logarithmic
plasma concentration-time profile.
Results
Patients’ Characteristics
From August 2007 to March 2009, 46 patients were
treated in this trial which was conducted at Fudan Uni-
versity Shanghai Cancer Center. 19 patients were
enrolled in the dose-escalation study. Another 27
patients were enrolled in the PK study. The patients’
baseline demographic and clinical characteristics are
s h o w ni nT a b l e1 .T h em o s tc o m m o nt u m o rl o c a t i o n s
were gastrointestinal tracts (73.9%). All patients had
received at least one prior chemotherapy regimen, 84.7%
prior surgery and 27% prior radiation. 45 had measur-
able lesions at baseline. Patients received a total of 133
cycles of therapy.
Dose Escalation
Five dose levels were investigated: 250 mg, 500 mg, 750
mg, 850 mg, and 1000 mg once daily). One additional
patient was included in the 250 mg-cohort due to with-
drawal of consent. Two DLTs at the dose level of 1000
mg/day were documented. One patient had grade 3
hypertension and the other grade 3 hand-foot syndrome
(HFS). Three additional patients were enrolled to the
850 mg-cohorts. None of the total six patients in the
850 mg-cohort experienced D L T s .T h e r e f o r e ,t h eM T D
for this dosing schedule was determined to be 850 mg
daily.
Pharmacokinetics
Plasma samples collected were analyzed by dose cohort
(in mg/day). Eleven patients of the 750 mg-single-dose
cohort continued to be enrolled to the 750 mg-multiple-
dose cohort after a 7-day-washed-out period while one
withdrew consent. Thus, the PK analysis population for
single-dosing was n = 8 for 500 mg-cohort, n = 12 for
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from the dose-escalation cohort provided consent to
participate in the PK cohort), and for multiple-dosing
(750 mg-cohort) n = 11 for 56 days.
Twenty eight patients were assessable for PK analysis.
Overall, mean PK parameters of apatinib after single
and multiple oral dose administration are summarized
in Table 2. For single dose evaluation, Cmax was
achieved in 3 to 4 hours after oral administration. The
plasma levels of apatinib varied considerably between
patients. For instance, the Cmax values varied between
926 and 4625 ng/ml after a single dose of 750 mg.
There was high inter-patient variability. The concentra-
tions of apatinib in plasma increased with dose. Cmax
and AUC0-24 showed a dose-dependent increase at
doses from 500 to 850 mg, whereas increased slightly
more than dose proportionally at dose of 850 mg, and
showed high inter-individual variability. The elimination
half-life of the terminal phase (t1/2 lz), estimated to be
approximately 9 hours, was constant over the three dose
levels.
For multiple-dose evaluation at 750 mg, the mean
Cmax was 2421 ng/ml on day 1, which increased to 2553
ng/ml by day 6, and the mean AUC0-24 was 19399 ng·h/
ml on day 1, which increased to 25449 ng·h/ml by day
6. There was no further increase in Cmax and AUC
beyond 6 days of multiple dosing, and this was similar
for the mean elimination t1/2. Steady-state conditions
were achieved by day 6, suggesting no accumulation
during 56 days of once-daily dosing.
Table 1 Patient Baseline Demographic and Clinical
Characteristics
Characteristic Patient
No %
Sex
Male 26 56.5
Female 20 43.5
Age, years
Median 51
Range 23-68
ECOG performance status
0 8 17.4
1 36 78.3
2 2 4.3
Prior Therapy 46
Chemotherapy (including cytokine and TKI)
12 1
21 0
≥31 5
Radiotherapy 13
Surgery 39
Other (Endocrine/Intervention)7
Measurability of baseline disease
Measurable 45 97.8
Unmeasurable 1 2.1
Primary tumor site
Gastrointestinal tract 34 73.9
Bronchus/Lung 3 6.5
Breast 3 6.5
Other 6 13
Abbreviation: ECOG, Eastern Cooperative Oncology Group
Table 2 Noncompartmental Mean Pharmacokinetic Parameters of Apatinib After Single or Multiple Oral Doses
Administration
PK parameter Single Oral Dose Multiple Oral Dose of 750 mg
500 mg
(n =8 )
750 mg
(n = 12)
850 mg
(n =8 )
Day 1
(n = 11)
Day 6
(n = 11)
Day 28
(n = 11)
Day 56
(n = 11)
Cmax, ng/ml
Geometric mean 1,521 2,379 2,833 2,421 2,553 2,210 1,854
CV% 75.1 55.9 90.0 68.5 52.8 45.5 51.2
tmax, hour
Median 3.5 3.0 4.0 3.0 4.0 4.0 3.0
Range 3.0-8.0 2.0-4.0 1.5-8.0 2.0-8.0 3.0-8.0 2.0-6.0 2.0-6.0
AUC0-24, ng·h/ml
Geometric mean 11,295 18,172 21,975 19,399 25,449 19,946 15,629
CV% 69.7 59.3 80.8 60.5 59.2 43.2 63.2
t1/2lz, hours
Mean 8.1 9.0 9.1 8.9 11.0 11.3 8.3
CV% 30.7 15.1 33.1 25.8 56.7 66.5 61.0
Abbreviations: Cmax, maximum plasma concentration; CV, coefficient of variation; tmax, time to reach Cmax; AUC0-24, area under plasma concentration-time curve
from 0 to 24 hour; t1/2lz, half-life associated with terminal slope of a semilogarithmic concentration-time curve.
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The safety population comprised all patients who had
received at least one dose of apatinib (N = 46). The
most frequently observed drug-related AEs were hyper-
tension (69.5%, 29 grade 1-2 and 3 grade 3-4), protei-
nuria (47.8%, 16 grade 1-2 and 6 grade 3-4), and hand-
foot syndrome (HFS) (45.6%, 15 grade 1-2 and 6 grade
3-4). Hypertension was manageable with antihyperten-
sive agents. About 10% of the patients who developed
HFS progressed to grade 3. The application of lotions or
moisturizers was useful for symptoms relief. Antibiotic
creams were introduced when infection was found. The
incidence of all treatment-related AE for each dose
levels was listed in Table 3. Treatment-related AEs were
Table 3 Incidence of Treatment-related Adverse Events in the Study Population for Each Cohort
Adverse Event NCI CTC Severity Grade Dose Cohort Total
250 mg 500 mg 750 mg 850 mg 1000 mg
No. % No. % No. % No. % No. % No. %
Hypertension 1-2 2 50 7 63.6 9 60 9 69.2 2 66.7 29 63
3-4 - - 2 13.3 - - 1 33.3 3 6.5
Proteinuria 1-2 - - 4 36.4 7 46.67 5 38.5 - 16 34.8
3-4 1 25.0 1 9 3 20 1 7.7 - - 6 13
Hand-Food Syndrome 1-2 - - 4 36.4 7 46.7 4 30.8 - - 15 32.6
3-4 - - 1 9 2 13.3 2 15.4 1 33.3 6 13
Pain 1-2 - - 4 36.4 4 26.7 3 23.1 1 33.3 12 26.1
3-4 - - 2 18.2 2 13.3 - - - - 4 8.7
Thrombocytopenia 1-2 1 25.0 2 18.2 6 40 2 15.4 1 33.3 12 26.1
3-4 - - 0 0 - - 1 7.7 - - 1 2.2
Fatigue 1-2 - - 1 9 4 26.7 4 30.8 1 33.3 10 21.7
3-4 - - - - 1 6.7 - - 1 33.3 2 4.3
Hyperbilirubinemia 1-2 - - - - - - 3 23.1 - - 3 6.5
3-4 1 25 - - - - - - - - 1 2.2
Transaminase Increased 1-2 2 50.0 1 9 6 40 3 23.1 1 33.3 13 28.3
3-4 - - 1 9 - - 2 15.4 1 33.3 4 8.7
Hemorrhage 1-2 - - 4 36.4 5 33.3 1 7.7 - - 10 21.7
3-4 - - 1 9 - - - - - - 1 2.2
Neutropenia 1-2 - - 2 18.2 7 46.7 4 30.8 3 100 16 34.8
3-4 - - 2 18.2 - - 2 15.4 - - 4 8.7
Diarrhea 1-2 - - 1 9 3 20 2 15.4 - - 6 13
3 - 4 ------------
Mucosal ulcers 1-2 - - 2 18.2 2 13.3 2 15.4 2 66.7 8 17.4
3-4 - - - - 2 13.3 - - - - 2 4.3
Infection 1-2 1 25.0 1 9 4 26.7 3 23.1 1 33.3 10 21.7
3 - 4 ------------
Dyspnea 1-2 - - - - - - 1 7.7 - - 1 2.2
3 - 4 ------------
Vomiting 1-2 - - 0 0 4 26.7 - - - - 4 8.7
3-4 - - - - - - 1 7.7 - - 1 2.2
Hoarseness 1-2 - - 1 9 2 13.3 1 7.7 - - 4 8.7
3 - 4 ------------
Albinism 1-2 - - - - 1 6.7 - - - - 1 2.2
3 - 4 ------------
Anemia 1-2 1 25.0 1 9 3 20 2 15.4 - - 7 15.2
3-4 - - - - - - 1 7.7 1 33.3 2 4.3
Rash 1-2 - - 1 9 1 6.7 1 7.7 - - 3 6.5
3 - 4 ------------
Anorexia 1-2 - - 2 18.2 3 20 1 7.7 1 33.3 7 15.2
3 - 4 ------------
Abbreviations: AE, adverse event; NCI CTC, National Cancer Institute Common Toxicity Criteria
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manageable.
For the two patients who experienced DLT, treatment
discontinuation and then re-initiation at a reduced dose
after recovery from the AEs was required. 15 patients
received at least one cycle of apatinib at the original
dose. Four patients discontinued treatment during cycle
1, one in the 250 mg dose group because of disease pro-
gression and three in the 1000-mg dose group because
of intolerable toxicity. Eighteen patients had a dose
reduction for different toxicities during extended treat-
ment (1 in 1000 mg group, 13 in 850 mg, and 4 in 750
mg). The mean duration of administration of apatinib
for the patients who experienced dose reduction was 5.4
months.
Tumor Response
Among the 45 patients with measurable disease, 4 with-
drew consent due to receiving other therapy, one experi-
enced intolerable toxicity, and three were lost to follow-
up. Thus, thirty-seven patients were evaluable for best
overall response. PR was noted in seven patients
(18.9%), SD 24 (64.9%), with a disease control rate of
83.8% at 8 weeks. Response was shown for patients at
each dose level in Table 4. Among the 7 patients who
achieved PR, one was diagnosed with GIST, one cancer
of unknown primary, one renal cell carcinoma, one gas-
tric cancer, and 3 colon cancer.
A 45-year-old female with metastatic rectal cancer invol-
ving the liver and lung, who had failed prior treatment of 2
cycles of FOLFOX4 regimen, 4 cycles of liver chemoembo-
lization, and 4 cycles of FOLFIRI, treated at 750 mg qd
dose level, had a partial response. Compared with the
baseline CT-scan, the same lesions on day 53 showed cav-
ity formation and decreased density. Further CT-scan con-
firmed partial response. Because of hand-foot syndrome,
diarrhea and stomatosis, she received reduced dose of
500 mg qd until disease progression (on day 255). Figure 1
A 65-year-old female with metastatic rectal cancer
involving the liver and lung, had prior treatment with 3
cycles of liver chemoembolization and 2 cycles of
FOLFOX4 regimen, who refused further chemotherapy,
treated at 750 mg qd dose level had a partial response.
Compared with the baseline CT-scan, the same lesions
on day 60 showed more than 30% decrease in the sum
of the longest diameter. Further CT-scan confirmed par-
tial response. The patient received 750 mg qd until dis-
ease progression (on day 215). Figure 2
Discussion
This study demonstrated that hypertension and HFS
were the main DLTs. Grade 3 toxicities in first 4 week
period were limited to patients receiving apatinib 1000
mg. The PK profile showed that apatinib once daily is
orally bioavailable in patients with solid tumors refrac-
tory to standard therapy. Apatinib exhibited quick
absorption, with Cmax reached in 3 to 4 hours. The
mean half-life, estimated to be approximately 9 hours,
was constant over all dose groups. Steady-state condi-
tions were achieved within 6 days of dosing, with no
accumulation during 56 days of once daily dosing of
apatinib. These PK and dose-escalation findings support
Table 4 Response Evaluation for Each Dose Cohort
Dose Cohort Response in evaluable patient
(n = 37)
Disease control (%)
CR PR SD PD CR+PR+SD
250 mg 0 1 1 1 2 (66.7)
500 mg 0 2 4 3 6 (66.7)
750 mg 0 2 9 0 11 (100)
850 mg 0 2 8 1 10 (90.9)
1000 mg 0 0 2 1 2 (66.7)
Total 0 7 24 6 31 (83.8)
Abbreviations: CR, complete response; PR, partial response; SD, stable disease;
PD, progressive disease.
Figure 1 Computerized tomography scans of the metastatic
tumors at baseline (A) and after 2 months (B) showing cavity
formation.
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II dose. Significant interpatient variability with apatinib
warrants dose modification to meet individual needs.
Apatinib was well tolerated by most patients at a daily
dose of ≤850 mg, and less toxicity greater than grade 3
was experienced by patients receiving the dose under
850 mg of apatinib. The most common AEs were hyper-
tension, proteinuria, and HFS. Hypertension has been
observed with all of the oral VEGF TKIs, as reported
previously [10]. Therefore, patients with pre-existing
hypertension were excluded from this trial as a safety
consideration. Systemic hypertension is believed to
occur because inhibition of VEGFR in arterial endothe-
lial cells decreases the release of nitric oxide, which acts
on arterial smooth muscle cells to cause vasodilation
[11]. Although 68% of patients in this study experienced
hypertension, it was easily controlled with medication.
VEGF is expressed in podocytes in the glomerulus, and
VEGF receptors are present on endothelial, mesangial,
and peritubular capillary cells. Proteinuria seems to be
related to the inhibition of VEGFR and usually regresses
with dose reduction. No patients developed glomerulo-
nephritis secondary to apatinib treatment.
Forty-five percent of patients experienced HFS, most
of which were grade 1 and 2. Eleven patients (23.9%)
experienced bleeding, most of which were found at
tumor sites, which is a little higher compared to other
VEGFR TKIs. Grade 3 alimentary tract hemorrhage was
noted in only 1 patient, mostly attributed to tumor
necrosis and active antiangiogenesis. Usually, cessation
of apatinib will eliminate this AE due to its relatively
short half-life. Although one-third of patients experi-
enced bone marrow suppression, most of these hemato-
logic events were grade 1 or 2 and were manageable.
Grade 3-4 neutropenia, thrombocytopenia, and anemia
were only seen in 8.7%, 2.2%, and 4.3% of patients,
respectively, and these AEs may have been related to
apatinib. VEGF receptors are present on bone marrow
progenitor cells, which would explain the occurrence of
bone marrow suppression [12].
During the extended course of treatment, 38% of
patients on reduced dose due to various toxicities con-
tinued to experience clinical benefit (disease control) for
as long as 5.4 months, suggesting a lower/tolerable dose
may be able to achieve greater disease control than the
predefined 8 weeks.
Significant antitumor activity was observed in patients
with measurable lesions. The majority (n = 31; 83.7%) of
these assessable patients exhibited either tumor shrink-
age or stabilization according to the RECIST criteria,
which is better than those of other TKIs. For sorafenib,
an SD of only 26% was reported in the phase I study
[6]. In a pooled analysis of 137 patients from 4 phase I
trials of sorafenib, only 2 evaluable patients (1.4%)
achieved PR and 38 (28%) had SD. Most of the patients
(70.8%) showed signs of disease progression by radiolo-
gical imaging [13]. Strong inhibitory effect on VEGFR-2
(IC50 =2 . 4 3n M )m a yp l a yak e yr o l ei nt h em o r ep r o -
minent anti-cancer activity noted in apatinib compared
to other VEGFR TKIs, but differences due to patient
selection could not be ignored, thus further prospective
comparative study may be required. Apatinib has shown
promising result for GIST, as one GIST patient who
failed imatinib achieved PR and have not progressed to
date. Duration of PR was 24 months.
Sunitinib is approved as first-line treatment for renal
cell carcinoma, with a 31% response rate and a pro-
longed progression-free survival (PFS) of 11 months
[14]. However, Saltz et al recently reported less activity
was noted for colorectal cancer with sunitinib mono-
therapy [15]. Among the 84 patients with colorectal can-
cer, only 1 achieved PR, and 13 stable disease. Sunitinib
did not demonstrate a clinically meaningful single-agent
objective response rate for patients with colorectal can-
cer refractory to standard chemotherapy. Also, sunitinib
has not been shown to be active against gastric adeno-
carcinoma. In a report from ASCO-GI in 2009, sunitinib
Figure 2 Tumor shrinkage was confirmed (B) after 4 months of
treatment with apatinib comparing with baseline (A).
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cancer [16]. Only 5 of 52 patients showed tumor con-
trol. Compared with sorafenib and sunitinib, apatinib
shows good anti-cancer effects for gastric and colorectal
cancer. Disease control rate of 81% was noted among
the 22 assessable patients with gastric and colorectal
cancer (n = 18), among whom 4 achieved PR.
Conclusions
The results of this study showed that apatinib was safe
and well tolerated, and exhibited substantial antitumor
activity at the dose of 750 mg once daily. Promising
antitumor activity of apatinib in patients with a broad
range of advanced solid tumors has been shown in this
study and apatinib is currently being evaluated further
in ongoing phase II/III trials (NCT00970138).
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